Fidelity Investments’s Checkpoint Therapeutics CKPT Stock Holding History

Fidelity Investments’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,613	Closed	-$11.6K	–	5350
2024 Q4	$11.6K	Buy	+3,613	New	+$12.2K	﹤0.01%	4414
2024 Q2	–	Sell	-150	Closed	-$308	–	5400
2024 Q1	$308	Buy	+150	New	+$299	﹤0.01%	4885
2023 Q4	–	Sell	-5	Closed	-$9	–	5463
2023 Q3	$9	Sell	5 -7,753	-100%	-$17.6K	﹤0.01%	5184
2023 Q2	$19.2K	Buy	7,758 +4,317	+125%	+$11.8K	﹤0.01%	3884
2023 Q1	$7.74K	Buy	3,441 +2,552	+287%	+$12.8K	﹤0.01%	4232
2022 Q4	$4.54K	Buy	+889	New	+$6.41K	﹤0.01%	4284
2022 Q3	–	Sell	-10	Closed	–	–	4902
2022 Q2	$0	Buy	+10	New	+$131	﹤0.01%	4962

Other funds holding CKPT

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

GLF

Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Fidelity Investments's CKPT Position: Q1 2025 in Review

Fidelity Investments sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 3,613 shares — an estimated $11.6K sold.

Fidelity Investments first reported a position in CKPT in Q2 2022 and held it in 7 quarters. The position peaked at $19.2K in Q2 2023. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

Fidelity Investments reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
Fidelity Investments sold 3,613 Checkpoint Therapeutics shares in Q1 2025, an estimated $11.6K.
Fidelity Investments first reported a position in Checkpoint Therapeutics in Q2 2022 and held it in 7 quarters.
Fidelity Investments's Checkpoint Therapeutics position peaked at $19.2K in Q2 2023.
84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Fidelity Investments's 13F filing for Q1 2025, filed 12 May 2025.